Regenerative Medicine Programme

Share Article

The Technology Strategy Board is to manage two further funding competitions as part of the £21.5 million Regenerative Medicine Programme.

The Technology Strategy Board is to manage two further funding competitions as part of the £21.5 million Regenerative Medicine Programme.

Regenerative Medicine Programme: Tools and Technologies will see the Technology Strategy Board, the Medical Research Council (MRC), the Biotechnology and Biological Sciences Research Council (BBSRC) and the Engineering and Physical Sciences Research Council (EPSRC) invest up to £8m in collaborative R&D projects. The intention is to establish consortia that address generic challenges in the development of cell based therapies and will lead to demonstrators with commercial applicability. Applications must be industrially led and are expected to consist of academic, industrial and end-user collaborators.

Through the Regenerative Medicine Programme: Developing Therapeutics 2 competition, the Technology Strategy Board is to invest up to £2.5m in commercial R&D projects in the area of regenerative medicine therapeutics. The aim is to support businesses in the preclinical, and particularly clinical, development of regenerative medicine therapeutics. Projects must be collaborative and led by a business.

Consortium-building workshops will take place on 17 February (Leeds), 21 February (Edinburgh) and 28 February (London).

The two-stage competitions open on 14 March 2011 and compulsory expressions of interest must be submitted by 20 April 2011. The deadline for receipt of full applications is 20 July 2011.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nick Sheppard